Anti-DNTT antibody (459-509) {FITC}

Referência NB-22-60067-100

Tamanho : 100ug

Solicitar mais informações

Contactar o distribuidor local :


Telefone : +1 850 650 7790

General Info

Host: Rabbit
Applications: CM/ELISA/ICC/IF/IHC/IP/WB
Reactivity: Chicken/Human/Monkey/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-DNTT (459-509) is suitable for use in Confocal Microscopy, ELISA, Immunocytochemistry, Immunofluorescence, Immunohistochemistry, Immunoprecipitation and Western Blot research applications.
Clonality: Polyclonal
Conjugation: FITC
Isotype: IgG
Purification: Affinity Purified
Concentration: 0.6 µg/µl
Dilution Range: WB: 1:1, 000
DB: 1:10, 000
ELISA: 1:10, 000
IP: 1:250
IHC: 1:250
ICC: 1:250
IF: 1:250
CFM: 1:250
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.

Information

Gene Symbol: DNTT
Gene ID: 1791
Uniprot ID: TDT_HUMAN
Immunogen Region: 459-509
Immunogen: Synthetic peptide taken within amino acid region 459-509 on human Terminal deoxynucleotidyltransferase protein.

Description

Function Template-independent DNA polymerase which catalyzes the random addition of deoxynucleoside 5'-triphosphate to the 3'-end of a DNA initiator. One of the in vivo functions of this enzyme is the addition of nucleotides at the junction (N region) of rearranged Ig heavy chain and T-cell receptor gene segments during the maturation of B- and T-cells.
Protein Name Dna Nucleotidylexotransferase
Terminal Addition Enzyme
Terminal Deoxynucleotidyltransferase
Terminal Transferase
Cellular Localisation Nucleus
Alternative Antibody Names Anti-Dna Nucleotidylexotransferase antibody
Anti-Terminal Addition Enzyme antibody
Anti-Terminal Deoxynucleotidyltransferase antibody
Anti-Terminal Transferase antibody
Anti-DNTT antibody
Anti-TDT antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance